Bionor Pharma

Bionor Pharma ASA
Type	Allmennaksjeselskap
Traded as	OSE: BIONOR
Industry	Biotechnology
Founded	2 january 1993
Headquarters	Oslo, Norway
Key people	Anker Lundemose (CEO), Lars Høie (Chair), Angus Dalgleish (Clinical Advisory Board), Jerome Zeldis (Board of Directors)
Products	Vaccine Soy protein Health care Natural Health Products
Revenue	NOK 109.499 million (2011)^[1]
Operating income	NOK 46 057 million (2011)^[1]
Profit	NOK 49 020 million (2011)^[1]
Total assets	NOK 253 395 million (2011)^[1]
Total equity	NOK 203 320 million (2011)^[1]
Number of employees	18 (2011)^[1]
Website	www.bionorpharma.com

Bionor Pharma ASA is a Norwegian biotechnology company, developing vaccines targeted at rapidly mutating virus infections such as HIV, Hepatitis C and Influenza. The company is also a leader in soy technology and has developed patented products for improved health and prevention of lifestyle-related diseases.^[2] It was founded by Cand.med. and Dr.philos. in protein and lipid research, Lars Høie.

Brands

The company was, under their name Nutri Pharma, formerly known for their soy-based product series within weight management (Nutrilett®, Scan Diet® and NutriPro®), cholesterol reduction (Abacor® and Abalon®) and menopausal and pre-menstrual symptoms (Nutri5®). The marketing and distribution rights for Nutri5 and NutriPro was in 2008 licensed to Nikken Europe^[3] for sale in 19 European countries, and in 2009 for Russia and CIS countries.^[3] The brand Nutrilett was in 2010 sold to the Orkla-owned health-supplements firm Axellus.^[4]

After the sale of their main brands, the company have moved focus to the vaccine business after the acquisition of biotechnology company Bionor Immuno in 2010.^[5]

Products in development

Per May, Bionor Pharma has four different vaccine candidates in their product pipeline, from preclinical phase to phase II, leading to phase III which is the last phase before regulatory approval and potential market entry.^[6]

Vacc-4x

Vacc-4x aims to generate immune responses to conserved domains, regions of the virus common to all strains of HIV, even if the virus mutates. Persistent immune responses against this part of the virus (the HIV p24 protein) has been shown to delay HIV disease progression. Vacc-4x is made of modified synthetic peptides targeting these conserved regions of the HIV p24. Upon immunization with Vacc-4x, potentially followed by reboosting vaccinations, Bionor's researchers are seeking to control virus infection for a longer period of time by exercising the patient's own immune system to seek out and kill virus-producing cells.

In phase II, 134 HIV-infected people from Europe and the US participated in a randomized, placebo-controlled study, where 93 randomly selected people where to receive Vacc-4x and 43 randomly selected people received a placebo injection. The patients were injected with either placebo or Vacc-4x in 28 weeks, followed up by 24 weeks without any injection.

77 people successfully completed the study (week 52); 25 from the placebo group and 56 from the Vacc-4x group. The placebo group (n=25) had a viral load set point (average of the last two viral load measurements before the end of the study) of 61,900 HIV-RNA/copies/ml (median), compared to the Vacc-4x group (n=56) that had a viral load set point of 22,300 HIV-RNA/copies/ml (median). This difference represents a reduction of 64% and is statistically significant (p=0.04).

Bionor Pharma is in the process of conducting two further clinical studies with the Vacc-4x, which can lead towards phase III, which include 1. Vacc-4x in combination with Celgene`s immune modulator Revlimid and 2. reboosting patients from the phase II study to investigate whether this can result in a further reduction in viral load.

Thirty three patients from USA and four European countries from the last study with Vacc-4x are taking part at ten clinics. The study was approved in all participating countries in Q4 2012, with startup of patient screening soon after.^[7]

Others

Other vaccines include humoral, antibody-mediated peptide-based therapeutic HIV-1 vaccine Vacc-C5, that aims to guide the immune system to seek out and kill HIV-infected cells, Vacc-HCV, aiming to treat chronic HCV infection that affects the liver and Vacc-Flu, which is in the preclinical phase of development.^[8]

References

This article is issued from Wikipedia - version of the Tuesday, November 10, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.